ISSN: 0034-8376
eISSN: 2564-8896



Piperacillin/Tazobactam in Continuous Infusion versus Intermittent Infusion in Children with Febrile Neutropenia



Fortino Solórzano-Santos, Department of Infectious Diseases, Hospital de Pediatría, Centro Medico Nacional Siglo XXI, IMSS, México D.F, México
Anaí Quezada-Herrera, Department of Neonatology, UMAE 48-Instituto Mexicano del Seguro Social (IMSS), León, Gto., Mexico
Yazmín Fuentes-Pacheco, High Specialty Medical Unit, Hospital de Pediatría, CMN SXXI, Instituto Mexicano del Seguro Social, Mexico City, Mexico
Genoveva Rodr√≠guez- Coello, Hospital para el Ni√Īo Poblano, Secretar√≠a de Salud, Puebla de Zaragoza, Puebla, Mexico
Carlos E. Aguirre-Morales, Centro Médico ABC, Mexico City, Mexico
Dassaev Izelo-Flores, Hospital General de Zona No. 20, Instituto Mexicano del Seguro Social, Puebla, Mexico
Onofre Mu√Īoz- Hern√°ndez, Research Directorate, Hospital Infantil de M√©xico "Federico G√≥mez", SSA, Mexico City, Mexico
María G. Miranda-Novales, Analysis and Synthesis of Evidence Research Unit, Coordinación de Investigación en Salud, Instituto Mexicano del Seguro Social, Mexico City, Mexico


Background: Febrile neutropenia (FN) is a common complication in children who receive chemotherapy for cancer. Objective: The objective of this study was to evaluate the clinical efficacy of the continuous versus intermittent infusion of piperacillin/ tazobactam (TZP) in febrile neutropenic pediatric patients. Methods: This is a non-blinded randomized controlled clinical trial. Eligible group consisted of hemato-oncological patients with FN who were candidates to receive TZP. Patients were randomized to one of two groups: Group 1 received antibiotic treatment through intravenous intermittent infusion of TZP 300 mg/kg/day based on piperacillin, divided into four doses, not exceeding 16 g/day; Group 2 received an initial TZP loading dose of 75 mg/kg infusion over 30 min, and then a continuous infusion of TZP 300 mg/kg/day through central line with pump over 24 h. Results: There were 176 episodes that could be assessed, 100 in Group 1 and 76 in Group 2. There was no statistically significant difference in treatment failure in the experimental group (continuous infusion) compared with the intermittent group, 21% versus 13% (p = 0.15). The increase in the absolute risk reduction was 0.08% (95% confidence interval 0.12-0.30), and the number needed to treat was 12.4. One patient in each group died. Conclusions: There were no differences in fever resolution, clinical cure rate, or mortality when comparing the continuous with the intermittent TZP infusion. (REV INVEST CLIN. 2019;71:283-90)



Keywords: Beta-lactams. Febrile neutropenia. Infusion. Piperacillin-tazobactam.